|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Washington |
|---|---|
| Collaborator: |
National Institute of Allergy and Infectious Diseases (NIAID) |
| Information provided by (Responsible Party): | Anna Wald, University of Washington |
| ClinicalTrials.gov Identifier: | NCT00495716 |
Purpose
The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners.
| Condition | Intervention | Phase |
|---|---|---|
|
Genital Herpes |
Drug: acyclovir |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission |
| Estimated Enrollment: | 500 |
| Study Start Date: | January 2008 |
| Estimated Study Completion Date: | September 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Episodic Treatment Arm
|
Drug: acyclovir
800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
|
|
Active Comparator: 2
Suppressive Therapy Arm
|
Drug: acyclovir
400 mg orally twice daily for 1 year
|
We plan to conduct a randomized controlled trial of chronic suppressive acyclovir, 400 mg orally twice daily (standard dose) versus episodic acyclovir for treatment of genital herpes recurrences. We will enroll 500 HSV-2 seropositive single persons (250 per arm), stratified by gender and history of symptomatic genital herpes, and prospectively follow them for 1 year to assess sexual behavior, adherence to therapy, and herpes-related quality of life. These outcomes will be measured by self-report in a confidential, computer-based assessment. We plan to use data from this trial to model the effect that increasing the proportion of sexually-active HSV-2 infected persons taking suppressive therapy will have on population-level incidence and prevalence of HSV-2.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Washington | |
| University of Washington Virology Research Clinic | |
| Seattle, Washington, United States, 98104 | |
| Principal Investigator: | Anna Wald, MD, MPH | University of Washington |
More Information
| Responsible Party: | Anna Wald, Principal Investigator, University of Washington |
| ClinicalTrials.gov Identifier: | NCT00495716 History of Changes |
| Other Study ID Numbers: | 32545-B, K23 AI071257-01A1 |
| Study First Received: | June 29, 2007 |
| Last Updated: | September 14, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
Herpes Genitalis Herpes Simplex Herpesviridae Infections DNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Genital Diseases, Male Genital Diseases, Female Acyclovir Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |